Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC By Ogkologos - August 20, 2025 501 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KRYSTAL-12 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Neoadjuvant Dabrafenib Plus Trametinib Has High Pathological Response Rates in Clinical... May 24, 2024 FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with... October 30, 2025 Male Patients with Cancer at Higher Risk of Severe Disease Course... August 26, 2020 Helicobacter Pylori Infection Modifies the Risk of Gastric Cancer Associated with... March 31, 2023 Load more HOT NEWS New targeted treatment for early breast cancer could reduce risk of... Transforming Cancer Clinical Trials for Better, Faster Results Targeted prostate cancer screening: Are we there yet? Resource Round-Up: Let’s Win Pancreatic Cancer
